CDX2-suppressed cancers were predominantly (66.7% of cases) of the CMS1 consensus molecular sub-type and less frequently belonged to CMS4, while no cases of CMS2 and CMS3 were included in the group. This evidence concerns the gene CDX2 and cancer.